BABA
Alibaba Group Holding Limited
BABA has the edge over THRM overall, supported by stronger modeled upside and stronger valuation.
THRM
Gentherm Incorporated
THRM offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
THRM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
THRM's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA has the edge over THRM in the historical PE scenario, which offers more potential upside but is not a forecast.
THRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $28.79 | — |
| Cheap | 24x | $6.79 | -76% |
| Fair | 36x | $10.21 | -65% |
| Expensive | 62x | $17.38 | -40% |
| Current | 103x | $28.79 | — |
Historical ranges are pointers, not guarantees.
THRM's PE is in its expensive range at 103x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BABA has the edge over THRM on the outlook, with more favorable profitability expectations.
THRM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for THRM, but weaker profitability. However, they disagree widely on these estimates.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA has the edge over THRM on earnings, with more consistent year-over-year improvement.
THRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +907% |
| Q3 2026 | $0.28 | -72% |
| Q2 2026 | $0.85 | -16% |
| Q1 2026 | $0.73 | -54% |
| Q4 2025 | $0.59 | -71% |
| Q3 2025 | $0.99 | -54% |
| Q2 2025 | $1.01 | -52% |
| Q1 2025 | $1.59 | +9.7% |
| Q4 2024 | $2.06 | +69% |
THRM's earnings per share have fallen from their peak: $0.28 over the past year, against $3.50 in mid-2021.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA has the edge over THRM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA has the edge over THRM on profitability, with a higher operating margin.
THRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $405.1M | +4.7% |
| Q2 2026 | $416.2M | +11% |
| Q1 2026 | $393.7M | +11% |
| Q4 2025 | $382.8M | +8.5% |
| Q3 2025 | $386.9M | +4.1% |
| Q2 2025 | $375.1M | -0.2% |
| Q1 2025 | $353.9M | -0.6% |
| Q4 2024 | $352.9M | -3.8% |
THRM's revenue has grown year over year for five quarters in a row: $405M last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | -2.6 points |
| Q2 2026 | 2.6% | -3.8 points |
| Q1 2026 | 2.9% | -2 points |
| Q4 2025 | 4.6% | -2.1 points |
| Q3 2025 | 6.2% | -2.5 points |
| Q2 2025 | 6.4% | -2.4 points |
| Q1 2025 | 4.8% | -0.3 points |
| Q4 2024 | 6.7% | -1.9 points |
THRM's operating margin was 3.5% last quarter, down 2.6 points from the same quarter a year ago.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
THRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.4M | -45% |
| Q2 2026 | -$1.2M | -103% |
| Q1 2026 | -$10.7M | +$17.5M |
| Q4 2025 | $6.7M | -51% |
| Q3 2025 | $46.5M | +75% |
| Q2 2025 | $36.2M | +104% |
| Q1 2025 | -$28.2M | -$6.6M |
| Q4 2024 | $13.6M | -52% |
THRM has the edge over BABA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has 2.4B diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
THRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -382K shares |
| 1 year | -0.2% | -76K shares |
| 3 years | -7.6% | -2.5M shares |
| 5 years | -8.7% | -2.9M shares |
| Available history | -7.9% | -2.6M shares |
THRM has the edge over BABA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $10M |
| Q1 2025 | — |
| Q4 2024 | $10M |
| Q3 2024 | $19.9M |
| Q4 2023 | $60M |
| Q3 2023 | $11.1M |
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA has the edge over THRM on leverage, with a lower net debt burden relative to earnings.
THRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.5x | Very low |
THRM's net debt is less than a year of its operating earnings (EBITDA).
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
THRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
THRM's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA has the edge over THRM on valuation relative to its sector.
THRM PE vs Consumer Cyclical Sector
| Metric | THRM | Sector median | Relative |
|---|---|---|---|
| PE | 103x | 18x | 471% above |
| PE % | 96 | 47 | 49 pts above |
THRM is trading at 103x earnings, a 471% premium to the Consumer Cyclical sector's median of 18x.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
THRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.4 | 5.2% below |
| 20 week MA | $35.7 | 19% below |
| 50 week MA | $34.1 | 16% below |
| 100 week MA | $33.4 | 14% below |
| 200 week MA | $43.3 | 33% below |
THRM is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has finished lower in three of the last six years. It's down 38% so far in 2026.
THRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.3 | $66.0 | +49% |
| 2021 | $66.0 | $82.4 | +25% |
| 2022 | $82.4 | $63.8 | -23% |
| 2023 | $63.8 | $52.4 | -18% |
| 2024 | $52.4 | $39.0 | -25% |
| 2025 | $39.0 | $37.2 | -4.7% |
| 2026 YTD | $37.2 | $28.8 | -23% |
THRM has the edge over BABA on returns for 2026, with the stronger performance.